FDA and drug development pipeline

By Shicheng Guo

J&J defends Darzalex with FDA approval for faster dosing
Rcpi: R/Bioconductor Package as an Integrated Informatics Platform for Drug Discovery: https://www.bioconductor.org/packages/release/bioc/vignettes/Rcpi/inst/doc/Rcpi.html
TAGRISSO: Targeted therapies to cancer that has tested positive for certain types of EGFR mutations. TAGRISSO specifically targets and blocks mutated EGFR found on cancer cells.
Fragment-based lead discovery (FBLD) also known as fragment-based drug discovery (FBDD)
BRAF is a human gene that encodes a protein called B-Raf. The gene is also referred to as proto-oncogene
The Drug Development Process: The Drug Development Process
In order to incentivize the development of new drugs, the FDA grants drug developers market exclusivity for a period of five years after a new drug is approved, during which time, no other firm is permitted to sell the drug, whether or not it is protected by a patent.
China National PGx Data Science Consortium (CNPGx)
KEGG DRUG: Methotrexate https://www.genome.jp/dbget-bin/www_bget?dr:D00142